Neoadjuvant Carboplatin and Docetaxel in Triple Negative Breast Cancer
The purpose of this study is to determine whether the combination of docetaxel and carboplatin is an effective treatment for patients with triple negative breast cancer.
Breast Cancer
DRUG: Docetaxel|DRUG: Carboplatin
Pathologic Complete Response, This is the complete disappearance of invasive cancer in the breast at the time of surgery, At the time of definitive surgery (approximately 4-5 months after beginning chemotherapy)
PRIMARY OBJECTIVE:

To determine whether neoadjuvant docetaxel and carboplatin will increase the pCR rate in TNBC compared to historical controls. Pathologic complete response (pCR) will be defined as no residual invasive breast cancer in the breast and ipsilateral axillary lymph node (ypT0-is ypN0).